{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:16:15Z","timestamp":1785402975463,"version":"3.56.0"},"reference-count":48,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: The evidence base for anticoagulation moved substantially between 2023 and 2026: a reframed atrial fibrillation (AF) guideline, new randomized data on extended treatment of cancer-associated venous thromboembolism (VTE), the first adequately powered head-to-head comparison of two direct oral anticoagulants (DOACs), the first randomized evidence for andexanet alfa, and mixed results for the factor XI inhibitor class. Real-world uptake remains incomplete. To review the 2023\u20132026 evidence changing anticoagulation practice, identify where bedside practice lags behind it, and outline the institutional adjustments needed to translate it into routine care. Methods: Narrative review. PubMed, EMBASE, and the Cochrane Library were searched from 2000 to January 2026, with hand-searching of society guidelines and regulatory documents; eligible sources were randomized trials, pre-specified subgroup analyses, prospective registries, systematic reviews, and society-endorsed guidelines. A targeted update in March 2026 captured practice-changing trials published after the primary search date, identifying COBRRA (published 11 March 2026). This is a narrative, non-systematic review reported in accordance with SANRA: no protocol was registered, topic selection is interpretive, and no formal risk-of-bias assessment or quantitative synthesis was undertaken. Recommendations are labeled by evidence basis. Results: Seven developments warrant attention: (1) the 2023 AF guideline\u2019s \u22652%\/year anticoagulation threshold, with sex-specific application and a 1\u20132%\/year shared decision zone; (2) API-CAT\u2014reduced-dose apixaban non-inferior to full dose for extended cancer VTE prevention (2.1% vs. 2.8%; adjusted subhazard ratio 0.76, 95% CI 0.41\u20131.41; pre-specified non-inferiority margin 2.00), with less bleeding (12.1% vs. 15.6%); (3) COBRRA\u2014apixaban substantially safer than rivaroxaban in acute non-cancer VTE (clinically relevant bleeding 3.3% vs. 7.1%; RR 0.46, 95% CI 0.33\u20130.65; major bleeding 0.4% vs. 2.4%; RR 0.16, 95% CI 0.06\u20130.40), without efficacy trade-off; (4) ANNEXA-I\u2014a modest hemostatic advantage for andexanet alfa over usual care (67.0% vs. 53.1%) at the cost of increased thrombosis (10.3% vs. 5.6%); (5) an asymmetric factor XI landscape in which class-level conclusions remain premature; (6) new special population data (ELDERCARE-AF, AZALEA sub-analyses by kidney function); and (7) a maturing but uneven stewardship evidence base. Conclusions: Three years of trials have produced concrete implications for how anticoagulation should be practiced now. The interval between publication and routine implementation remains the largest practical problem in the field, and institutional stewardship structures are a major mechanism for closing it.<\/jats:p>","DOI":"10.3390\/jcm15155946","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:09:42Z","timestamp":1785398982000},"page":"5946","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticoagulation Stewardship in the Era of Practice-Changing Evidence: A Narrative Review of Recent Trials and Their Bedside Translation"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-4574","authenticated-orcid":false,"given":"Mansour","family":"Aljabry","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-1876","authenticated-orcid":false,"given":"Ghazi","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1001\/jama.2016.16201","article-title":"US emergency department visits for outpatient adverse drug events, 2013\u20132014","volume":"316","author":"Shehab","year":"2016","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jama.2021.13844","article-title":"US emergency department visits attributed to medication harms, 2017\u20132019","volume":"326","author":"Budnitz","year":"2021","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY)","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF)","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE)","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation (ENGAGE AF-TIMI 48)","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e007633","DOI":"10.1161\/JAHA.117.007633","article-title":"Frequency and outcomes of reduced dose non\u2013vitamin K antagonist anticoagulants: Results from ORBIT-AF II","volume":"7","author":"Steinberg","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non\u2013vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"ref_15","first-page":"e12512","article-title":"Anticoagulation stewardship: A new frontier for safer anticoagulation care","volume":"5","author":"Barnes","year":"2021","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014A scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomized trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: The ARISTOPHANES study","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/j.1538-7836.2011.04336.x","article-title":"The AVAIL ME Extension: A multinational Middle Eastern survey of venous thromboembolism risk and prophylaxis","volume":"9","author":"Mokhtari","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"IDSA and SHEA guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative bridging anticoagulation in patients with atrial fibrillation (BRIDGE)","volume":"373","author":"Douketis","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant (PAUSE)","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.23736\/S2724-5683.24.06546-3","article-title":"Italian Registry in the Setting of Atrial Fibrillation Ablation with Rivaroxaban\u2014IRIS","volume":"72","author":"Lavalle","year":"2024","journal-title":"Minerva Cardiol. Angiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"109\u2013279","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Carrier","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2510703","article-title":"Bleeding risk with apixaban vs. rivaroxaban in acute venous thromboembolism","volume":"394","author":"Castellucci","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor\u2013associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014Full cohort analysis (RE-VERSE AD)","volume":"377","author":"Pollack","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamacardio.2025.3393","article-title":"Safety of factor XI inhibition with abelacimab in atrial fibrillation by kidney function: A prespecified analysis of the AZALEA-TIMI 71 randomized clinical trial","volume":"10","author":"Patel","year":"2025","journal-title":"JAMA Cardiol."},{"key":"ref_33","unstructured":"Bristol Myers Squibb (2025). Update on Phase 3 Librexia ACS Trial [Press Release], Bristol Myers Squibb."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"Asundexian for secondary stroke prevention","volume":"394","author":"Sharma","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s11239-025-03142-x","article-title":"Safety of factor XI inhibitors compared to factor X inhibitors in atrial fibrillation: A systematic review and meta-analysis","volume":"58","author":"Markides","year":"2025","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: A multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: The AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer (CARAVAGGIO)","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity: Updated guidance from the SSC of the ISTH","volume":"19","author":"Martin","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11239-015-1189-3","article-title":"Implementation of a hemostatic and antithrombotic stewardship program","volume":"40","author":"Reardon","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s11096-019-00834-2","article-title":"The effect of hospital-based antithrombotic stewardship on adherence to anticoagulant guidelines","volume":"41","author":"Dreijer","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/0897190013514091","article-title":"Development of an anticoagulation stewardship program at a large tertiary care academic institution","volume":"28","author":"Padron","year":"2015","journal-title":"J. Pharm. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/j.1538-7836.2010.04051.x","article-title":"Effectiveness of pharmacist-participated warfarin therapy management: A systematic review and meta-analysis","volume":"8","author":"Saokaew","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Dreijer, A.R., Kruip, M.J.H.A., Diepstraten, J., Polinder, S., Brouwer, R., Mol, P.G., Croles, F.N., Kragten, E., Leebeek, F.W., and van den Bemt, P.M. (2020). Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0235048"},{"key":"ref_45","unstructured":"The Joint Commission (2026, June 01). National Patient Safety Goals: NPSG.03.05.01\u2014Reduce the Likelihood of Patient Harm Associated with the Use of Anticoagulant Therapy. Hospital Program, Effective January 2026. Available online: https:\/\/digitalassets.jointcommission.org\/api\/public\/content\/9ca80055182b4274842a5780a94f2c82."},{"key":"ref_46","unstructured":"Centers for Medicare & Medicaid Services (2026, June 01). 2025 MIPS Quality Measure 326: Atrial Fibrillation and Atrial Flutter\u2014Chronic Anticoagulation Therapy. Quality Payment Program Documentation, 2024. Available online: https:\/\/mdinteractive.com\/mips_quality_measure\/2025-mips-quality-measure-326."},{"key":"ref_47","unstructured":"Centers for Medicare & Medicaid Services (2024). Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments. Fed. Regist., 89, 97710\u201398643."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"World Health Organization (2023). WHO Model List of Essential Medicines, WHO. [23rd ed.]. (addition of apixaban).","DOI":"10.1530\/ey.19.13.1"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/5946\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:40:19Z","timestamp":1785400819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/5946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":48,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15155946"],"URL":"https:\/\/doi.org\/10.3390\/jcm15155946","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}